ral Register Notice: FDA has determined the regulatory review period for Asahi Glass Co.’s Zioptan (tafluprost) is 3,881 days for extending a patent which claims the human drug product. Zioptan is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. To view this notice, click here.
